Pfizer's RSV vaccine shows promising results in preventing severe infection in infants.
TL;DR Summary
Pfizer's experimental RSV vaccine was 82% effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to final trial data. The vaccine, currently under review by health regulators in the US and Europe, could become the first maternal vaccine available to prevent the disease in infants if approved by the FDA by August. The shot failed to meet a second main goal of reducing non-severe illness in infants.
- Pfizer RSV vaccine 82% effective vs severe infection in infants, final data shows (April 5) Reuters
- Final data shows Pfizer RSV vaccine 82 percent effective in infants when given to pregnant mothers The Hill
- Late-stage RSV vaccine trials show 'exciting promise,' some scientists say CNN
- RSV vaccine effective in infants when administered during pregnancy Contemporary Pediatrics
- New RSV vaccine may prevent illness in infants, seniors Medical Xpress
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
79%
363 → 78 words
Want the full story? Read the original article
Read on Reuters